US EditionPfizer moves forward with once-daily weight-loss pill
- Pfizer will launch a once-daily version of danuglipron for weight loss, based on positive early-stage trial data.
- A twice-daily danuglipron version was discontinued in December due to patient tolerance issues.
- Danuglipron, like Wegovy and Ozempic, aids weight loss as a GLP-1 drug.
44 Articles
44 Articles
Pfizer avanza con un proyecto de una pastilla para bajar de peso al tiempo que busca recuperarse de su crisis pospandemia, pero el fabricante de medicamentos dio pocas pistas sobre qué influyó exactamente en esa decisión.El jueves, Pfizer informó los esperados resultados de un estudio en el que participaron 20 personas sobre una píldora contra la obesidad que anteriormente tuvo problemas debido a sus efectos secundarios. En el nuevo estudio, Pfi…
Pfizer moving ahead with plans for once-daily weight loss pill
(The Hill) - Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as treatments including Ozempic and Zepbound. The pharmaceutical giant said clinical evaluation of once-daily doses its oral GLP-1 agonist candidate danuglipron demonstrated "encouraging" data. Dose optimization studies are planned. Pfizer had been looking into a twice-daily version of danuglipron last year but decided…
Pfizer moving ahead with plans for once-daily weight loss pill
(The Hill) - Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as treatments including Ozempic and Zepbound. The pharmaceutical giant said clinical evaluation of once-daily doses its oral GLP-1 agonist candidate danuglipron demonstrated "encouraging" data. Dose optimization studies are planned. Pfizer had been looking into a twice-daily version of danuglipron last year but decided…
Pfizer moving ahead with plans for once-daily weight loss pill
(The Hill) - Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as treatments including Ozempic and Zepbound. The pharmaceutical giant said clinical evaluation of once-daily doses its oral GLP-1 agonist candidate danuglipron demonstrated "encouraging" data. Dose optimization studies are planned. Pfizer had been looking into a twice-daily version of danuglipron last year but decided…
Pfizer moving ahead with plans for once-daily weight loss pill
(The Hill)—Pfizer announced Thursday plans to proceed with an oral daily weight loss medication in the same drug category as treatments such as Ozempic and Zepbound. The pharmaceutical giant said clinical evaluation of once-daily doses its oral GLP-1 agonist candidate danuglipron demonstrated "encouraging" data. Dose optimization studies are planned. Pfizer had been looking into a twice-daily version of danuglipron last year but decided against …
Coverage Details
Bias Distribution
- 65% of the sources are Center
To view factuality data please Upgrade to Premium
